ClinicalTrials.gg
DrugRead study by study

Niraparib clinical trials

Also written Zejula, MK-4827 and JNJ-64091742.

studies test it
151
open now
35
in phase 3
19
first study started
2008
ClinicalTrials.gov finds 238 studies for niraparib. How that becomes 151 here

Every study that search finds has been read, to see whether and how it gives niraparib. ClinicalTrials.gov counts as of Nov 15, 2026. How drug pages count

  1. 238Found by its intervention search · See all 238 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 215 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
  2. −1
    Mention it without giving it — earlier treatment, a protocol code, a title naming another drug
  3. 237Give niraparib to participants
  4. −25Observe patients on it, or give it outside a trial
  5. −2Use it as a tool: an imaging tracer or a test of drug response
  6. −59Give it beside what is tested
  7. 151Test it: the count on this site

Get an email when these change. Save the niraparib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
27 Mar 2017 · ZEJULA · NDA 208447 (FDA, Drugs@FDA)
European Union
16 Nov 2017 · Zejula · EMEA/H/C/004249 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Niraparib
105
Niraparib Tosylate Monohydrate
4
formerly MK-4827
2
Niraparib Oral Product
2
Niraparib oral capsule
2

Brand

Zejula
48

Development codes

MK-4827
19
JNJ-64091742
3
GSK3985771
1

Studies by the year they started

151 studies that test it; most in 2019 (24)

Studies that test niraparib, by start year
YearStudies
20081
20105
20111
20131
20142
20153
20166
20179
201812
201924
202020
202119
202212
202317
202412
20256
20261

By phase

A phase 1/2 study counts in both.

Early Phase 1
4
Phase 1
46
Phase 2
95
Phase 3
19
Phase 4
5

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 43 · Other 108

Tesaro, Inc. (18) · Janssen Research & Development, LLC (5) · Massachusetts General Hospital (5) · GlaxoSmithKline (5) · Zai Lab (Shanghai) Co., Ltd. (5) · Hoffmann-La Roche (3) · Abramson Cancer Center at Penn Medicine (3) · M.D. Anderson Cancer Center (3)

Often tested with

Tested in the same studies.

Dostarlimab (20) · Atezolizumab (9) · Abiraterone (7) · Trastuzumab (7) · Abiraterone Acetate (6) · Cobimetinib (6) · Prednisone (6) · Olaparib (6)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

New treatments tested with it · 8 most studied

New when their studies opened, with niraparib beside them; studies of each.

Reaching primary completion within a year · 22, 4 in phase 3

Studies that test niraparib, phase 3 first.

Studies

Open first, then newest update. How each study uses niraparib has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.

Testing it · 151

See all 151 studies that test niraparib →

Behind its US label · 2 — the studies the FDA label of ZEJULA describes

From the Clinical Studies section of ZEJULA (2026-07), as openFDA has it. A study the site does not hold is left out.

Tested on its own · 67 — no other medicine in its arm

Showing 20 of 67. See all 67 →

Tested with established drugs · 12 — they are given beside it
Tested in a combination · 72 — another drug in the study is under test too

Showing 20 of 72. See all 72 →

Beside an established treatment under test · 8 — an approved drug, surgery or radiation is what the study tests

Tested with niraparib: Bevacizumab 2 · Surgery or a procedure 2 · atezolizumab 1 · Cisplatin 1 · Radiation 1

Beside a new treatment under test · 48 — a new drug, cell therapy or vaccine is what the study tests

New treatments tested with niraparib: dostarlimab 13 · anlotinib 3 · tuvusertib 2 · cetrelimab 1 · DNA Polymerase Theta Inhibitor GSK4524101 1 · oregovomab 1 · bemcentinib 1 · azenosertib 1

Showing 20 of 48. See all 48 →

Beside supportive care · 3 — a supportive treatment or test is studied
Observed · 25 — patients on it are followed, or it is given outside a trial

Showing 20 of 25. See all 25 →

As a tool · 2 — an imaging tracer or a test of drug response

Codes

What other systems call niraparib · ClinicalTrials.gg INT005538

  • MeSH (NLM) C545685niraparibConfirmed ClinicalTrials.gov, NLM, Wikidata
  • UNII (FDA) HMC2H89N35NIRAPARIBConfirmed FDA, NLM, Wikidata
  • RxNorm 1918231Confirmed FDA, Wikidata
  • Wikidata Q25326660niraparibConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C80059NiraparibConfirmed FDA, Wikidata
  • DrugBank DB11793One source Wikidata

Also registered as niraparib hydrochloride (UNII L4JFC1PHCI) and niraparib tosylate (UNII 195Q483UZD).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.

Start the discussion